Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01998113
Other study ID # IIBSP-ADO-2013-153
Secondary ID
Status Completed
Phase N/A
First received November 8, 2013
Last updated March 23, 2015
Start date March 2013
Est. completion date May 2014

Study information

Verified date November 2013
Source Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact n/a
Is FDA regulated No
Health authority Spain: Ethics Committee
Study type Observational

Clinical Trial Summary

Since the publication in the New England Journal of Medicine (NEJM) in 2000 of the Langer's trial comparing glyburide vs insulin in the treatment of gestational diabetes mellitus (GDM), additional studies of oral agents for the treatment of GDM have been published (observational, randomized controlled trials (RCT), and trials using other drugs like metformin).

Some meta-analysis to summarize the evidence have been published: Nicholson 2009 (including 4 RCT addressing different drugs), Dhulkotia 2010 (including 6 RCT addressing different drugs, the meta-analysis combining all drugs altogether), Gui 2013 (including 5 RCT addressing metformin vs insulin).

Oral agents are increasingly used for the treatment of GDM. Investigators aim to update the evidence on RCTs comparing glyburide and metformin vs insulin or between them and summarize this evidence using meta-analysis tools. Specifically, investigators aim at producing distinct meta-analyses for each one of the three drug comparisons. This information is not available in the literature since the most recent systematic reviews specifically dealing on oral agents for the treatment of GDM have addressed a single drug comparison (Gui 2013) or have combined different drug comparisons into a single meta-analysis (Dhulkotia 2010)


Description:

This project involves the systematic review of RCT addressing the use of glyburide or metformin for the treatment of GDM. The review will include RCT comparing these drugs versus insulin or making direct comparisons between the two oral agents in pregnant women with GDM.

Investigators have pre-specified a series of maternal and fetal outcomes of interest.

A comprehensive electronic search strategy will be complemented with a search of bibliographies from relevant studies and the contact of authors from the eligible studies regarding issues on study design or information on primary outcomes.

The risk of bias of included studies will be analyzed and this information used to perform sensitivity analyses. If possible, data from original studies will be pooled into relative risks for dichotomous outcomes and mean differences for continuous outcomes.

Heterogeneity will be explored for all the analyses. Analyses will be undertaken using a fixed effects model that will be repeated using a random effects model in case of substantial heterogeneity.

Results of the systematic review will be published following PRISMA guidance.


Recruitment information / eligibility

Status Completed
Enrollment 2509
Est. completion date May 2014
Est. primary completion date May 2014
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- RCT

- GDM

- comparing Glyburide vs Insulin, Metformin vs Insulin or Metformin vs Glyburide

- data on fetal and/or maternal outcomes

- full text available

Exclusion Criteria:

- significant overlap with other articles of the same group

Study Design

Time Perspective: Retrospective


Intervention

Drug:
Glyburide vs Insulin trials
Affecting groups 1 and 2
Metformin vs Insulin trials
Affecting groups 3 and 4
Metformin vs Glyburide trials
Affecting groups 5 and 6

Locations

Country Name City State
Spain Hospital de la Santa Creu i Sant Pau Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Country where clinical trial is conducted

Spain, 

References & Publications (6)

Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs insulin in management of gestational diabetes: a systematic review and metaanalysis. Am J Obstet Gynecol. 2010 Nov;203(5):457.e1-9. doi: 10.1016/j.ajog.2010.06.044. Epub 2010 Aug 24. Review. — View Citation

Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational diabetes: a meta-analysis. PLoS One. 2013 May 27;8(5):e64585. doi: 10.1371/journal.pone.0064585. Print 2013. — View Citation

Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000 Oct 19;343(16):1134-8. — View Citation

Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: a systematic review. Obstet Gynecol. 2009 Jan;113(1):193-205. doi: 10.1097/AOG.0b013e318190a459. Review. — View Citation

Rowan JA, Hague WM, Gao W, Battin MR, Moore MP; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med. 2008 May 8;358(19):2003-15. doi: 10.1056/NEJMoa0707193. Erratum in: N Engl J Med. 2008 Jul 3;359(1):106. — View Citation

Silva JC, Fachin DR, Coral ML, Bertini AM. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. J Perinat Med. 2012 Jan 10;40(3):225-8. doi: 10.1515/jpm-2011-0175. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary 3rd trimester glycated hemoglobin mean difference of 3rd trimester glycated hemoglobin 3rd trimester of pregnancy No
Primary total maternal weight gain mean difference of total maternal weight gain (as defined by the authors) during pregnancy No
Primary severe maternal hypoglycemia relative risk of severe maternal hypoglycemia (as defined by the authors) from enrollment to delivery No
Primary preeclampsia relative risk of preeclampsia (as defined by the authors) during pregnancy or puerperium No
Primary cesarean section relative risk of cesarean section (as defined by the authors) at the end of pregnancy No
Primary gestational age at birth mean difference of gestational age at birth (as defined by the authors) at birth No
Primary preterm birth relative risk of preterm birth (as defined by the authors) at birth No
Primary birthweight mean difference of birthweight (as defined by the authors) at birth No
Primary macrosomia relative risk of macrosomia (defined as birthweight >=4000 g) at birth No
Primary large-for-gestational age newborn relative risk of large-for-gestational age newborn (as defined by the authors) at birth No
Primary small-for-gestational age newborn relative risk of small-for-gestational age newborn (as defined by the authors) at birth No
Primary neonatal hypoglycemia relative risk of neonatal hypoglycemia (as provided by the authors) in the neonatal period No
Primary perinatal mortality relative risk of perinatal mortality (as defined by the authors) in the perinatal period No
Primary insulin treatment relative risk of insulin treatment (for trials comparing metformin vs glyburide) from enrollment to delivery No
Secondary fasting blood glucose mean difference of fasting blood glucose (as defined by the authors) in the period from enrollment to delivery No
Secondary postprandial blood glucose mean difference of postprandial blood glucose (as defined by the authors) in the period from enrollment to delivery No
Secondary maternal weight gain since enrollment mean difference of maternal weight gain since enrollment (as defined by the authors) in the period from enrollment to delivery No
Secondary pregnancy-induced hypertension relative risk of pregnancy-induced hypertension (as defined by the authors) during pregnancy No
Secondary induction of labour relative risk of induction of labour (as described by the authors) at the end of pregnancy No
Secondary cord C peptide mean difference of cord C peptide (as defined by the authors) at birth No
Secondary cord insulin mean difference of cord insulin (as defined by the authors) at birth No
Secondary abnormal 1 min Apgar relative risk of abnormal 1 min Apgar (defined as lower than 7) at birth No
Secondary abnormal 5 min Apgar relative risk of abnormal 5 min Apgar (defined as lower than 7) at birth No
Secondary obstetric trauma relative risk of obstetric trauma (as defined by the authors) at birth No
Secondary severe neonatal hypoglycemia relative risk of severe neonatal hypoglycemia (as defined by the authors) in the neonatal period No
Secondary neonatal jaundice relative risk of neonatal jaundice (as defined by the authors) in the neonatal period No
Secondary significant respiratory distress relative risk of significant respiratory distress (described as respiratory distress syndrome or requiring respiratory support) in the neonatal period No
Secondary stillbirth relative risk of stillbirth (as defined by the authors) in the antenatal period No
Secondary neonatal mortality relative risk of neonatal mortality (as defined by the authors) in the neonatal period No
Secondary Neonatal Intensive Care Unit (NICU) admittance relative risk of NICU admittance (as defined by the authors) in the neonatal period No
See also
  Status Clinical Trial Phase
Recruiting NCT06099574 - A Study on the Oral Health Status of Pregnant Women With Gestational Diabetes and Its Correlation With Oral Flora
Completed NCT02744300 - Balance After Baby Intervention for Women With Recent Gestational Diabetes N/A
Completed NCT02890693 - Improving Cardio-metabolic and Mental Health in Women With Gestational Diabetes Mellitus and Their Offspring N/A
Completed NCT02384226 - User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
Completed NCT02436551 - Gestational Diabetes in Central Asia: Prevalence and Management
Recruiting NCT02275845 - Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus Phase 3
Recruiting NCT04621396 - The Next Generation Longitudinal Birth Cohort Diabetes Study
Completed NCT01916694 - Trial of Remote Evaluation and Treatment of Gestational Diabetes Mellitus N/A
Completed NCT01931280 - A Transgenerational e-Intervention for Gestational Diabetics and Their Offspring N/A
Not yet recruiting NCT01637727 - Long Term Effects of Gestational Diabetes Mellitus in a Population of Parous Women N/A
Completed NCT01565564 - Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes N/A
Recruiting NCT00550979 - Gestational Diabetes Mellitus and Implications for Cardiovascular Disease Risk N/A
Completed NCT00460018 - Diet, Exercise, and Breastfeeding Intervention Program for Women With Gestational Diabetes (DEBI Trial) Phase 2
Not yet recruiting NCT04915716 - Effect of Fasting Time Before Cesarean Section on Neonatal Blood Glucose in Pregnant Women With Gestational Diabetes Mellitus
Completed NCT04422821 - Flash Glucose Monitoring in Gestational Diabetes Mellitus: Study Protocol for a Randomized Controlled Trial N/A
Recruiting NCT04369313 - Effect of DCC on Neonatal Jaundice and Blood Gas Analysis in Infants Born to GDM Mothers N/A
Recruiting NCT05348863 - SPARK- a Digital Platform to Improve Self-management of Gestational Diabetes N/A
Recruiting NCT04272840 - The Impact of Glycemic Index Education on Lowering Dietary GI in Gestational Diabetes Mellitus N/A
Completed NCT02588729 - A Mobile Smartphone Application to Promote a Healthy Diet and Physical Activity Among Pregnant Women With GDM - RCT N/A
Completed NCT01922791 - Nutrition and Pregnancy Intervention Study N/A